Back to News
Market Impact: 0.35
MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
Source: zacks.com
Corporate EarningsCorporate Guidance & OutlookCompany Fundamentals
McKesson beat estimates for Q2 fiscal 2027, supported by specialty growth and higher prescription volumes, and raised its guidance. Shares nevertheless dipped after hours; the article provides no figures for the beat, guidance increase, or stock move.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
MCK0.75
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request